EyePoint (EYPT) Gross Margin (2018 - 2026)

EyePoint (EYPT) reported Gross Margin of 24.14% for Q1 2026, down 7257.0% on a YoY basis from 0.34% in Q1 2025, and down 38.92% sequentially from 39.52% in Q4 2025.

EyePoint (EYPT) Gross Margin (2018 - 2026) Analysis & Trends

EyePoint (EYPT) has 9 years of Gross Margin data on file, last reported at 24.14% in Q1 2026.

  • For the quarter ending Q1 2026, Gross Margin fell 7257.0% year-over-year to 24.14%; the trailing twelve-month figure through Mar 2026 stood at 76.51% (down 1679.0% YoY), and the FY2025 full-year result was 93.41%, up 199.0% from the prior year.
  • Gross Margin declined to 24.14% in Q1 2026, from 39.52% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 96.91% in Q2 2025 to a low of 24.14% in Q1 2026.
  • A 5-year average of 77.87% and a median of 85.97% in 2022 frame the typical range for Gross Margin.
  • Across the five-year window, Gross Margin jumped 2526 bps in 2023 and sank 7257 bps in 2026, its largest moves.
  • Tracing EYPT's Gross Margin over 5 years: stood at 67.63% in 2022, then jumped by 37 bps to 92.89% in 2023, then rose by 0 bps to 92.96% in 2024, then slumped by 57 bps to 39.52% in 2025, then plunged by 39 bps to 24.14% in 2026.
  • Business Quant data shows EYPT's Gross Margin at 24.14% in Q1 2026, 39.52% in Q4 2025, and 25.36% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 88.95%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 86.85%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 91.79%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 90.68%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 EyePoint 358.61 Mn 136.07 Mn 168,000.00 24.14%

Historic Data

Download Data
DateValue
Mar 31, 2026 24.14%
Dec 31, 2025 39.52%
Sep 30, 2025 25.36%
Jun 30, 2025 96.91%
Mar 31, 2025 96.71%
Dec 31, 2024 92.96%
Sep 30, 2024 93.01%
Jun 30, 2024 85.22%
Mar 31, 2024 93.50%
Dec 31, 2023 92.89%
Sep 30, 2023 92.09%
Jun 30, 2023 80.32%
Mar 31, 2023 91.67%
Dec 31, 2022 67.63%
Sep 30, 2022 85.97%
Jun 30, 2022 85.01%
Mar 31, 2022 80.88%
Dec 31, 2021 73.73%
Sep 30, 2021 79.85%
Jun 30, 2021 78.60%